Key result
Serum neuron-specific enolase is being investigated for detecting preoperative brain injury in infants and toddlers with congenital heart disease, though no results are reported in the abstract.
Why the study?
Preoperative risk stratification of brain injury in congenital heart disease may reduce adverse neurological outcomes, but whether serum neuron-specific enolase can detect baseline brain damage before surgery is unclear.
Can serum neuron-specific enolase (sNSE) demonstrate the presence of a significant incidence of baseline brain damage in infants and toddlers with congenital heart disease before undergoing interventions?
Observational
Can serum neuron-specific enolase (sNSE) demonstrate the presence of a significant incidence of baseline brain damage in infants and toddlers with congenital heart disease before undergoing interventions?
This study investigates whether serum neuron-specific enolase can serve as a preoperative biomarker to detect baseline brain injury in infants and toddlers with congenital heart disease.
Answers are grounded in this paper and cite their sources.
Serum neuron-specific enolase may support preoperative neurological risk stratification in CHD; leaves open whether it improves outcomes.
A significant number of patients presenting with Congenital heart diseases (CHD) experience concomitant neurological disorders, whether subclinical or overt. These neurological manifestations of brain injury may become manifest after undergoing surgery for CHD correction. Therefore, risk stratifying patients with high chances of developing adverse neurological outcomes before undergoing their surgeries can decrease these unfavorable outcomes by ensuring optimal surgical precautions. Serum neuron-specific enolase (sNSE), a known marker of neuronal damage, has been used in this study to detect level of brain injury. The purpose of this study is to investigate the role of serum neuron-specific enolase in detecting brain injury in infants and toddlers with congenital heart disease prior to performing surgery. This study seeks to answer the research question, can sNSE demonstrate the presence of a significant incidence of baseline brain damage in CHD patients, before undergoing any interventions.
No takes yet. Share an insight, caveat, or question.
Ghafar et al. (2021) conducted an observational in Congenital heart disease. Serum neuron-specific enolase (sNSE) was evaluated on Baseline brain damage. Serum neuron-specific enolase is being investigated for detecting preoperative brain injury in infants and toddlers with congenital heart disease, though no results are reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: